Immunexpress Looks To Leverage U.S. Anti-Infection Incentives With Unique Sepsis Diagnostic
This article was originally published in The Gray Sheet
The Seattle company's SeptiCyte system is designed to directly quantify molecular markers of sepsis from patient blood samples and tell doctors the probability that a patient has sepsis within four hours, allowing for aggressive treatment of sepsis or, if the test result is negative, preventing unnecessary antibiotics.
You may also be interested in...
The market for diagnostic and infection control products will see continued growth as hospitals and other providers look to the technology sector to help fight the battle against health care-associated infections and antibiotic-resistant organisms.
Start-ups developing technologies to help hospitals avoid preventable medical errors known as “never events” are developing solutions to nosocomial infections, retained surgical objects, pressure ulcers, and medication errors.
Yuhan’s oncology drug lazertinib is set to expand its indications in Korea to the first-line treatment of EGFR mutation-positive advanced NSCLC, based on new top-line Phase III data showing clinical benefits for all patient sub-groups.